Pföhler Claudia, Müller Cornelia Sl, Hasselmann Dirk O, Tilgen Wolfgang
The Saarland University Hospital, Department of Dermatology, Homburg/Saar, Germany.
J Med Case Rep. 2008 Aug 26;2:283. doi: 10.1186/1752-1947-2-283.
Insulin allergy may occur in patients treated with subcutaneous applications of insulin preparations. Besides additives in the insulin preparation such as protamine, cresol, and phenol, the insulin molecule itself may be the cause of the allergy. In the latter case, therapeutic options are rare.
A 68-year-old man with poorly controlled type 2 diabetes mellitus received different insulin preparations subcutaneously while on oral medication. Six to eight hours after each subcutaneous application, he developed pruritic plaques with a diameter of >15 cm at the injection sites that persisted for several days. Allergologic testing revealed positive reactions against every insulin preparation and against protamine. Investigation of serum samples demonstrated IgG antibodies against human and porcine insulin. We treated the patient with human insulin using an ultra-rush protocol beginning with 0.004 IU and a rapid augmentation in dose up to 5 IU. Therapy was accompanied by antihistamine therapy. Subsequent conversion to therapy with glargine insulin (6 IE twice daily) was well-tolerated.
As reported in this case, desensitization with subcutaneously administered human insulin using an ultra-rush protocol in patients with an insulin allergy may present an easy form of therapy that is successful within a few days.
胰岛素过敏可能发生在接受皮下注射胰岛素制剂治疗的患者中。除了胰岛素制剂中的添加剂,如鱼精蛋白、甲酚和苯酚外,胰岛素分子本身也可能是过敏的原因。在后一种情况下,治疗选择很少。
一名68岁的2型糖尿病控制不佳的男性在口服药物治疗期间皮下接受了不同的胰岛素制剂。每次皮下注射后6至8小时,他在注射部位出现直径大于15厘米的瘙痒性斑块,持续数天。过敏测试显示对每种胰岛素制剂和鱼精蛋白均呈阳性反应。血清样本检测显示存在针对人胰岛素和猪胰岛素的IgG抗体。我们采用超快速方案,从0.004国际单位开始,快速增加剂量至5国际单位,对该患者使用人胰岛素进行治疗。治疗过程中同时给予抗组胺治疗。随后转换为甘精胰岛素治疗(每日两次,每次6国际单位),耐受性良好。
如本病例所报道,对于胰岛素过敏患者,采用超快速方案皮下注射人胰岛素进行脱敏治疗可能是一种简便的治疗方法,且能在数天内取得成功。